Patient preference study: shot vs infusion for immunotherapy
Treatments studied
Part of Cancer, Digestive system, Kidney & urinary, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This study compares two ways to take immunotherapy drugs (nivolumab or pembrolizumab): as a shot under the skin (subcutaneous) versus an infusion into a vein (intravenous). It looks at which method patients prefer and is for people with certain advanced cancers where these drugs are already approved.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be able to read and write in English.
- Your doctor says you are eligible to receive nivolumab or pembrolizumab for your cancer type.
- Your cancer must be one of the types where these drugs are approved (like kidney, melanoma, lung, or others).
- You should either be starting immunotherapy for the first time, or currently be on treatment with certain immunotherapy drugs.
- You cannot have had a severe allergic reaction to nivolumab or pembrolizumab in the past.
- You cannot have received a donated organ or tissue transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares giving the immunotherapy drug nivolumab as a shot under the skin at home versus in the clinic. It is for people with certain cancers who are already taking or starting nivolumab.
This study looks at how kidney cancer patients feel about getting their treatment at home versus at the clinic, and asks their doctors for their views too. It is for patients already on certain standard treatments and aims to understand preferences that may improve care.
This study looks at how common medicines might interact with immunotherapy (a treatment that helps your immune system fight cancer). Participation could help doctors learn how to better manage side effects and dosing for patients on these treatments.
This trial tests whether giving certain immunotherapy drugs less often than usual is safe and still works well for people with advanced stomach, liver, or lung cancer. It might mean fewer hospital visits while still controlling the cancer.
This study tests a combination of three drugs (relatlimab, ipilimumab, and nivolumab) as a first treatment for advanced melanoma that cannot be removed by surgery. All participants will receive the drug combination, and the study will look at safety and how well it works.
This trial studies whether an individualized “neoantigen” cancer vaccine given to immune cells (dendritic cells) plus nivolumab can improve outcomes in people with liver cancer and/or colorectal cancer that has spread only to the liver. It focuses on tumors that can be removed with curative surgery (with or without local ablation) and on people with good enough liver and overall health.
Hear when a new Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.